Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

Breast Cancer Clinical Trial

Official title:

Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00418236
• Other study ID #: 3068A1-400
• Status: Completed
• Phase: Phase 4
• First received: January 2, 2007
• Last updated: August 17, 2010
• Start date: October 2006
• Est. completion date: April 2010

Study information

• Verified date: December 2007
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

It has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense. However, while breast density may be a risk factor, the etiology of the relationship between breast cancer and breast density is not understood. Furthermore, it is well recognized that breast cancer can still develop in women whose breasts are not dense.

At menopause, the amount of breast glandular tissue and stroma naturally decreases due to a lack of hormonal stimulation. This is characterized as a decrease in the mammographic density. Although certain medications, including hormone therapy (HT) and dopamine antagonists can increase breast density, these effects are reversible upon discontinuation of the specific agent. Other medications such as the selective estrogen receptor modulators (SERM), raloxifene (RAL) and tamoxifen, have been shown to not affect breast density and allow the normal age-related changes to occur. The effects of bazedoxifene (BZA), a new SERM, on breast density are not known. The purpose of this study is to examine the effect of BZA on breast density changes over 24 months in postmenopausal women. The results may be useful for clinicians to understand the effect of BZA on breast density and its mammographic effects.

This is an observational, multicenter, double-blind, randomized, placebo- and active comparator-controlled study. It is also an ancillary that will use women who are already participants in a phase 3 trial for fracture reduction (protocol 3068A1-301-WW; primary study). In the primary study, subjects received BZA 20 mg, BZA 40 mg, RAL 60 mg, or placebo. This ancillary study will request a subset of participants to use their mammograms taken in this study. Their mammogram will be digitized by a central imaging center. A single radiologist will perform the quantifications of breast density from the digitized mammograms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: April 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 63 Years

Eligibility

1. Each subject must have participated or is currently participating in study 3068A1 301, and must satisfy all of the following criteria

2. Has completed 24 months of treatment.

3. Had a mammogram at the baseline visit and at the month 24 visit, and both are original films that are technically acceptable for reading.

4. Was less than or equal to 62 years of age at the time of study randomization in the primary study.

5. Was at least 80% compliant with test article administration.

6. Did not take any medications 6 months prior to screening in the primary study or during the first 24 months of the study that could cause a change in breast density.

7. Was enrolled at a site that has at least 4 subjects meeting all of the above inclusion criteria.

8. Was enrolled at a clinical site that is still participating in the primary study.

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Breast Cancer

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Bulgaria,  Canada,  Chile,  Croatia,  Denmark,  Estonia,  Mexico,  Netherlands,  Poland,  Romania,  South Africa,